An open label, randomized, parallel group, controlled, interventional clinical study to evaluate the efficacy and safety of â??Madhav Rasayanâ?? tablet as an adjuvant to Standard treatment in mild to moderate COVID-19 subjects - NI

Shri Vishwavati Ayurved Chikitsalaya and Research Centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Gender: Either male or non-pregnant, non-lactating female aged > 18-60 < years (both inclusive).
•2. Subjects with RT-PCR confirmed diagnosis of COVID-19
•3. Subjects with mild to moderate COVID-19 infection having Respiratory rate >= 24/min and SpO2 > 90% on room air
•4. Subjects willing to give written informed consent
•5. Subjects able to take the drug orally and comply with the study protocol
•6. Women of child bearing potential must have a negative urine pregnancy test prior to study entry

•1 Subjects with persistent vomiting
•2 Critically ill subjects
•3 Patient with Shock
•4 Subjects with known active hepatitis, tuberculosis
•5 Subjects with altered mental state if on medication
•6 Subjects with multiple organ failure requiring ICU monitoring and treatment
•7 Subjects with respiratory failure and requiring mechanical ventilation
•8 Subjects with any concurrent medical condition or uncontrolled, clinically significant systemic disease (e.g. heart failure, hypertension, liver disease, diabetes, anemia etc.) that, in the opinion of investigator precludes the subjectâ??s participation in the study or interferes with the interpretation of the study results.
•9 Subjects with known history of serology tests positive for hepatitis B, hepatitis C, or human immunodeficiency virus.
•10 Patient who have participated in another investigational study within 3 months prior to enrolment in this study
•11 Investigators, study personnel, sponsorâ??s representatives and their first-degree relatives.
•12 Pregnant and or lactating subjects

发起方

Shri Vishwavati Ayurved Chikitsalaya and Research Centre